Editas wins Australia nod for gene editing trial (EDIT:NASDAQ)
· seekingalpha.com
Editas Medicine (EDIT) stock gains as Wells Fargo upgrades after Australia clears the first-in-human trial for the firm's gene editing drug, EDIT-401. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...